Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
P/E ratio for Kymera Therapeutics, Inc. (KYMR)
P/E ratio as of 2023: -10.11
According to Kymera Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -10.11. At the end of 2022 the company had a P/E ratio of -8.87.
P/E ratio history for Kymera Therapeutics, Inc. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -10.11 |
| 2022 | -8.87 |
| 2021 | -31.09 |
| 2020 | -24.48 |
| 2019 | -35.87 |
| 2018 | -31.20 |